Cytogenetic responses to a 5-day dosing schedule of decitabine in patients (Pts) with myelodysplastic syndromes (MDS).
Cytogenetic responses to a 5-day dosing schedule of decitabine in patients (Pts) with myelodysplastic syndromes (MDS). J Clin Oncol. 2008 May 20; 26(15_suppl):7030.